Metagenomi Q2 2026: $120.7M cash, IND for MGX-001 hemophilia A on track for 4Q 2026

Metagenomi Therapeutics, Inc.

Cash, equivalents, and marketable securities $120.7M as of June 30, 2026; runway through 4Q 2027.
IND application for MGX-001 (hemophilia A) on track for 4Q 2026; IND-enabling studies expected complete by end of Q3 2026.
R&D expenses flat at $22.5M YoY; G&A down to $6.0M from $7.0M in Q2 2025.
Two scientific posters won Top Poster Awards at 2026 ISTH Congress in Paris.
Plans to initiate clinical trials in 2027 subject to regulatory clearance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.